☆ 4.7 Review

FDA-Approved Monoclonal Antibodies for Unresectable Hepatocellular Carcinoma: What Do We Know So Far?

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2023)

Related references

Note: Only part of the references are listed.

Article Oncology

Initial therapeutic results of atezolizumab plus bevacizumab for unresectable advanced hepatocellular carcinoma and the importance of hepatic functional reserve

Tetsu Tomonari et al.

Summary: This study analyzed the association between modified albumin-bilirubin (mALBI) grade and therapeutic efficacy of atezolizumab plus bevacizumab (Atezo+Bev) treatment for unresectable hepatocellular carcinoma (u-HCC). The results showed that patients with mALBI 1+2a had better treatment response and longer progression-free survival.

CANCER MEDICINE (2023)

Add to Collection

Article Oncology

Does first-line treatment have prognostic impact for unresectable HCC?-Atezolizumab plus bevacizumab versus lenvatinib

Atsushi Hiraoka et al.

Summary: This study compared the therapeutic efficacy of atezolizumab plus bevacizumab and lenvatinib as first-line treatment for unresectable hepatocellular carcinoma (u-HCC). The results showed that patients who received atezolizumab plus bevacizumab had a better prognosis in terms of PFS and OS compared to those who received lenvatinib.

CANCER MEDICINE (2023)

Add to Collection

Article Oncology

Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma

Aditya Juloori et al.

Summary: This study investigated the safety and efficacy of stereotactic body radiation therapy (SBRT) with immunotherapy in patients with hepatocellular carcinoma (HCC). The results showed that the combination of SBRT with nivolumab plus ipilimumab had better survival and efficacy compared to immunotherapy alone in HCC patients, suggesting the need for further investigation.

INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS (2023)

Add to Collection

Article Oncology

Exposure-Response Analyses of Tremelimumab Monotherapy or in Combination with Durvalumab in Patients with Unresectable Hepatocellular Carcinoma

Xuyang Song et al.

Summary: This study evaluated the use of a novel single-dose regimen of tremelimumab in patients with unresectable hepatocellular carcinoma. The analysis found that there was no significant correlation between tremelimumab exposure and efficacy or safety, but the minimum serum drug concentration had an impact on patient survival. The findings suggest that the use of tremelimumab in unresectable hepatocellular carcinoma may have clinical utility.

CLINICAL CANCER RESEARCH (2023)

Add to Collection

Article Gastroenterology & Hepatology

Neutrophil-lymphocyte ratio predicts early outcomes in patients with unresectable hepatocellular carcinoma treated with atezolizumab plus bevacizumab: a multicenter analysis

Toshifumi Tada et al.

Summary: This study aimed to investigate the predictive value of neutrophil-to-lymphocyte ratio (NLR) on outcomes in patients with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab plus bevacizumab. The results showed that NLR can predict overall survival in these patients, but not progression-free survival. There were significant differences in treatment response and adverse events between patients with different NLR levels.

EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Hyperprogressive disease in patients with unresectable hepatocellular carcinoma receiving atezolizumab plus bevacizumab therapy

Kazuki Maesaka et al.

Summary: In a study of 88 Japanese patients with HCC receiving atezolizumab plus bevacizumab, 10.2% of patients exhibited hyperprogressive disease (HPD) and had significantly shorter overall survival, with elevated baseline neutrophil-to-lymphocyte ratio (NLR) being identified as a risk factor for HPD.

HEPATOLOGY RESEARCH (2022)

Add to Collection

Article Gastroenterology & Hepatology

Safety and efficacy of atezolizumab plus bevacizumab in patients with unresectable hepatocellular carcinoma in early clinical practice: A multicenter analysis

Makoto Chuma et al.

Summary: In patients with unresectable hepatocellular carcinoma, ATZ + BV treatment may offer significant benefits in those who meet IMbrave150 criteria or have low NLR.

HEPATOLOGY RESEARCH (2022)

Add to Collection

Article Gastroenterology & Hepatology

Early experience of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma BCLC-B stage patients classified as beyond up to seven criteria - Multicenter analysis

Atsushi Hiraoka et al.

Summary: This study retrospectively evaluated the therapeutic response of atezolizumab plus bevacizumab combination therapy in u-HCC patients classified as UT-7 out/multiple, showing favorable therapeutic response with less influence on hepatic function.

HEPATOLOGY RESEARCH (2022)

Add to Collection

Article Oncology

Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice

Yuka Hayakawa et al.

Summary: The study examined the efficacy and safety of atezolizumab plus bevacizumab therapy in patients with unresectable hepatocellular carcinoma based on different treatment lines, showing better clinical outcomes in 1st-line therapy. An early AFP response at 6 weeks could serve as a predictor of disease progression.

INVESTIGATIONAL NEW DRUGS (2022)

Add to Collection

Article Gastroenterology & Hepatology

Updated efficacy and safety data from IMbrave150: Atezolizumab plus bevacizumab vs. sorafenib for unresectable hepatocellular carcinoma

Ann-Lii Cheng et al.

Summary: The study demonstrated that atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma patients led to improved survival outcomes. After updated analysis, atezolizumab plus bevacizumab maintained its position as the first-line treatment option for advanced hepatocellular carcinoma.

JOURNAL OF HEPATOLOGY (2022)

Add to Collection

Article Oncology

Nivolumab versus sorafenib in advanced hepatocellular carcinoma (CheckMate 459): a randomised, multicentre, open-label, phase 3 trial

Thomas Yau et al.

Summary: First-line nivolumab treatment did not significantly improve overall survival compared with sorafenib in patients with advanced hepatocellular carcinoma, but clinical activity and a favorable safety profile were observed in some patients.

LANCET ONCOLOGY (2022)

Add to Collection

Editorial Material Oncology

Durvalumab Plus Tremelimumab: A Novel Combination Immunotherapy for Unresectable Hepatocellular Carcinoma

Masatoshi Kudo

LIVER CANCER (2022)

Add to Collection

Article Radiology, Nuclear Medicine & Medical Imaging

Comparative assessment of standard and immune response criteria for evaluation of response to PD-1 monotherapy in unresectable HCC

Sara Lewis et al.

Summary: This study evaluated the response of HCC patients to PD-1 monotherapy, showing an ORR of 21% without cases of pseudoprogression. Factors such as age, MELD/Child-Pugh scores, AFP levels, prior transarterial radioembolization (TARE), and tumor size were found to be predictive of PD and/or poor OS.

ABDOMINAL RADIOLOGY (2022)

Add to Collection

Article Oncology

The Prognostic Value of Neutrophil-to-Lymphocyte Ratio and Platelet-to-Lymphocyte Ratio in Patients with Hepatocellular Carcinoma Receiving Atezolizumab Plus Bevacizumab

Jing-Houng Wang et al.

Summary: Atezolizumab plus bevacizumab has been approved as the first-line treatment for unresectable hepatocellular carcinoma. This study examined the efficacy and safety of this treatment in real-world clinical practice and found that it is effective and well-tolerated. In addition, neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) were identified as independent prognostic factors for progression-free survival (PFS).

CANCERS (2022)

Add to Collection

Article Oncology

Evaluating the Role of Hepatobiliary Phase of Gadoxetic Acid-Enhanced Magnetic Resonance Imaging in Predicting Treatment Impact of Lenvatinib and Atezolizumab plus Bevacizumab on Unresectable Hepatocellular Carcinoma

Ryu Sasaki et al.

Summary: This study evaluated the use of liver-biliary phase of EOB-MRI to predict the therapeutic effect of lenvatinib and atezolizumab plus bevacizumab. The results showed that in the lenvatinib group, the liver-biliary phase did not stratify progression-free survival (PFS) differently, while in the atezolizumab plus bevacizumab group, patients with heterogeneous type and hyperintensity type had significantly shorter PFS.

CANCERS (2022)

Add to Collection

Article Medicine, Research & Experimental

Transarterial Radioembolization Versus Atezolizumab-Bevacizumab in Unresectable Hepatocellular Carcinoma: A Matching-Adjusted Indirect Comparison of Time to Deterioration in Quality of Life

Ion Agirrezabal et al.

Summary: For patients with hepatocellular carcinoma, the quality of life that different treatments can offer is an important aspect to consider. This study indirectly compared the time to deterioration of quality of life for transarterial radioembolization using SIR-Spheres and atezolizumab-bevacizumab. The study showed that both treatments may maintain quality of life over a similar time period and have longer-lasting effects compared to sorafenib.

ADVANCES IN THERAPY (2022)

Add to Collection

Article Oncology

Current Role of Atezolizumab Plus Bevacizumab Therapy in the Sequential Treatment of Unresectable Hepatocellular Carcinoma

Shohei Komatsu et al.

Summary: Atezolizumab plus bevacizumab therapy appears to be effective for advanced hepatocellular carcinoma regardless of liver function and treatment line. Lenvatinib treatment post-failure of the former therapy may also be effective, with caution needed for potential liver function deterioration.

ANTICANCER RESEARCH (2022)

Add to Collection

Article Oncology

Real-world efficiency of lenvatinib plus PD-1 blockades in advanced hepatocellular carcinoma: an exploration for expanded indications

Xuqi Sun et al.

Summary: This study evaluated the efficacy and prognostic factors of lenvatinib plus PD-1 blockades in patients with advanced hepatocellular carcinoma. Tumor occupation >= 50% volume of liver (TO >= 50%) had a negative impact on treatment response, while invasion in Vp4 did not significantly affect the treatment outcomes. Lenvatinib plus PD-1 blockades can improve the survival of patients with advanced hepatocellular carcinoma.

BMC CANCER (2022)

Add to Collection

Article Oncology

Lenvatinib plus pembrolizumab for systemic therapy-naive and -experienced unresectable hepatocellular carcinoma

Chi-Jung Wu et al.

Summary: This study evaluated the efficacy and safety of lenvatinib plus pembrolizumab for unresectable hepatocellular carcinoma (uHCC) patients. The results showed a high disease control rate (DCR) and no adverse effect on liver function score in both systemic therapy-naive and -experienced uHCC patients.

CANCER IMMUNOLOGY IMMUNOTHERAPY (2022)

Add to Collection

Article Oncology

Alpha-Fetoprotein as a Potential Surrogate Biomarker for Atezolizumab plus Bevacizumab Treatment of Hepatocellular Carcinoma

Andrew X. Zhu et al.

Summary: This study investigated the potential of on-treatment alpha-fetoprotein (AFP) response as a surrogate biomarker for prognosis in hepatocellular carcinoma patients receiving atezolizumab + bevacizumab. The results showed that AFP cutoffs of >= 75% decrease and <= 10% increase from baseline at 6 weeks could distinguish responders and patients with disease control. These AFP cutoffs were associated with longer overall survival and progression-free survival in patients, particularly those with hepatitis B virus etiology.

CLINICAL CANCER RESEARCH (2022)

Add to Collection

Article Oncology

Lenvatinib plus TACE with or without pembrolizumab for the treatment of initially unresectable hepatocellular carcinoma harbouring PD-L1 expression: a retrospective study

Song Chen et al.

Summary: This retrospective study compared the clinical outcomes of pembrolizumab-lenvatinib-TACE and lenvatinib-TACE sequential therapy in Chinese uHCC patients with initial PD-L1 expression, indicating that the former had a higher conversion rate, longer OS and PFS.

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

AGA Clinical Practice Guideline on Systemic Therapy for Hepatocellular Carcinoma

Grace L. Su et al.

Summary: This article presents the research and recommendations for systemic therapies for HCC, providing evidence-based guidelines for patients.

GASTROENTEROLOGY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Therapeutic efficacy of atezolizumab plus bevacizumab treatment for unresectable hepatocellular carcinoma in patients with Child-Pugh class A or B liver function in real-world clinical practice

Takaaki Tanaka et al.

Summary: There was no significant difference in the best response between CP-A and -B patients treated with Atez/Bev. Analysis showed that CP-A patients had better progression-free survival (PFS) and overall survival (OS) rates compared to CP-B patients. The median PFS and OS were also significantly different between different Child-Pugh score (CPS) groups and modified albumin-bilirubin grade (mALBI) groups.

HEPATOLOGY RESEARCH (2022)

Add to Collection

Review Biotechnology & Applied Microbiology

Monoclonal antibodies for malaria prevention

Maya Aleshnick et al.

Summary: Monoclonal antibodies are specific proteins that can be used as prophylactics or therapeutics for infectious diseases. Although the high cost of production is a limitation, preliminary research shows that monoclonal antibodies have potential in preventing malaria.

MOLECULAR THERAPY (2022)

Add to Collection

Review Gastroenterology & Hepatology

Which role for predictors of response to immune checkpoint inhibitors in hepatocellular carcinoma?

Alessandro Rizzo et al.

Summary: This article discusses the available evidence regarding predictive biomarkers of response to immunotherapy in hepatocellular carcinoma (HCC) patients, highlighting the need for further research on biochemical predictors of response to immune checkpoint inhibitors (ICIs) in HCC.

EXPERT REVIEW OF GASTROENTEROLOGY & HEPATOLOGY (2022)

Add to Collection

Article Oncology

Safety and efficacy of atezolizumab plus bevacizumab in elderly patients with hepatocellular carcinoma: A multicenter analysis

Toshifumi Tada et al.

Summary: This study demonstrates that atezolizumab plus bevacizumab can be used efficaciously and safely in elderly patients with unresectable hepatocellular carcinoma (HCC), with age not being a significant factor affecting treatment outcomes and adverse event rates.

CANCER MEDICINE (2022)

Add to Collection

Article Public, Environmental & Occupational Health

Indirect Comparisons via Sorafenib for the Comparative Effectiveness of Two PD-1/PD-L1 Inhibitors to Treat Advanced Hepatocellular Carcinoma Patients without Prior Systemic Therapies

Yawen Jiang et al.

Summary: This study compared the efficacy of two combination therapies, atezolizumab plus bevacizumab (AB) and lenvatinib plus pembrolizumab (LP), for advanced hepatocellular carcinoma (HCC). The results showed that AB had better efficacy in overall survival (OS) and progression-free survival (PFS) compared to sorafenib, while LP had significantly better efficacy in PFS but not in OS. The second-order comparison found that AB was slightly more efficacious in OS and similarly efficacious in PFS compared to the LP regimen.

CLINICAL EPIDEMIOLOGY (2022)

Add to Collection

Article Oncology

Atezolizumab/Bevacizumab vs. Lenvatinib as First-Line Therapy for Unresectable Hepatocellular Carcinoma: A Real-World, Multi-Center Study

Beom Kyung Kim et al.

Summary: In the first-line treatment of unresectable HCC, ATE/BEV and LENV had comparable clinical efficacy and safety, with no significant differences observed.

CANCERS (2022)

Add to Collection

Article Oncology

Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma

Gohar Shahwar Manzar et al.

Summary: This study reports the first experience of combined radiation therapy and modern systemic therapy for hepatocellular carcinoma (HCC). The combination therapy is safe and well-tolerated, with a faster recovery of absolute lymphocyte counts (ALCs) compared to other treatment regimens, which may serve as a favorable prognosticator.

CANCERS (2022)

Add to Collection

Article Oncology

Different Radiological Criteria for Early Tumor Response Evaluation in Patients With Unresectable Hepatocellular Carcinoma Treated With Anti-PD-1 Antibody Plus Bevacizumab

Ying Xu

Summary: This study aimed to compare different radiological criteria for evaluating early tumor response in patients with unresectable hepatocellular carcinoma (uHCC) treated with anti-PD-1 antibody plus bevacizumab. The results showed that the evaluations based on Choi and rChoi criteria were significantly correlated with overall survival (OS), and patients identified as responders by these criteria had significantly better OS than non-responders.

FRONTIERS IN ONCOLOGY (2022)

Add to Collection

Article Health Care Sciences & Services

Transarterial Chemoembolization for Hepatocellular Carcinoma: Why, When, How?

Evgenia Kotsifa et al.

Summary: HCC is the most common primary liver malignancy associated with liver cirrhosis and chronic liver disease. Key risk factors for HCC development include viral infections, alcoholic liver disease, and nonalcoholic fatty liver disease. Treatment options for HCC depend on tumor burden, liver function, and patient's health status, with surgical resection, transplantation, ablation, TACE, and systemic therapy being potential strategies.

JOURNAL OF PERSONALIZED MEDICINE (2022)

Add to Collection

Review Biology

An Insight into the Novel Immunotherapy and Targeted Therapeutic Strategies for Hepatocellular Carcinoma and Cholangiocarcinoma

Eleni-Myrto Trifylli et al.

Summary: HCC and CCA are highly malignant forms of primary liver cancers. Carcinogenesis of hepatocellular and bile duct is a complex process influenced by genetic and epigenetic alterations, environmental factors, and the gut microbiome. Recent studies have identified the crucial role of intestinal microbiota in the pathogenesis and opened new possibilities for novel therapeutic strategies such as immunotherapy, improving the overall survival of cancer patients.

LIFE-BASEL (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Targeted Therapies for Hepatocellular Carcinoma Treatment: A New Era Ahead-A Systematic Review

Christos Damaskos et al.

Summary: This review article discusses the characteristics of hepatocellular carcinoma (HCC) and presents the progress in HCC therapy through targeted therapies. The development of efficient molecular markers and alternative therapeutic targets are emphasized.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Gastroenterology & Hepatology

Potential feasibility of atezolizumab-bevacizumab therapy in patients with hepatocellular carcinoma treated with tyrosine-kinase inhibitors

Benedetta Stefanini et al.

Summary: Real-world data indicate that less than one-third of hepatocellular carcinoma patients treated with tyrosine-kinase inhibitors are potentially eligible to atezolizumab-bevacizumab according to the registration trial criteria. These patients have a longer survival than the non-eligible ones. If the selection criteria of atezolizumab-bevacizumab trial are maintained in clinical practice, tyrosine-kinase inhibitors will remain the most used systemic therapy for hepatocellular carcinoma patients.

DIGESTIVE AND LIVER DISEASE (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Immunotherapy as a Therapeutic Strategy for Gastrointestinal Cancer-Current Treatment Options and Future Perspectives

Evangelos Koustas et al.

Summary: Gastrointestinal cancer is a highly lethal malignancy and remains a major challenge for cancer treatment options. Despite current treatment strategies, the survival rates for patients with advanced disease are still low. Understanding the molecular mechanisms that influence tumor progression and developing optimal therapeutic strategies are urgently needed. Immunotherapeutic agents are currently being developed and assessed through clinical trials, offering new modalities and combination treatments.

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2022)

Add to Collection

Article Biochemistry & Molecular Biology

Molecular correlates of clinical response and resistance to atezolizumab in combination with bevacizumab in advanced hepatocellular carcinoma

Andrew X. Zhu et al.

Summary: This study analyzed tumor samples from patients with hepatocellular carcinoma and found that combination therapy with atezolizumab and bevacizumab was effective in treating this type of cancer. Patients with high expression of VEGF Receptor 2, regulatory T cells, and myeloid inflammation signatures showed better outcomes with the combination therapy compared to atezolizumab alone. These findings provide insights into baseline immune and genetic features that can identify patients who will benefit from the combination therapy of atezolizumab and bevacizumab in advanced hepatocellular carcinoma.

NATURE MEDICINE (2022)

Add to Collection

Article Oncology

Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy

Takayuki Matsumae et al.

Summary: This study investigated the potential of cell-free DNA (cfDNA)/circulating tumor DNA (ctDNA) as biomarkers for predicting the therapeutic outcome in u-HCC patients treated with anti-programmed cell death1-ligand1 (PD-L1)/vascular endothelial growth factor (VEGF) therapy. Patients with high levels of cfDNA showed poorer response rates and shorter survival compared to those with low levels of cfDNA. The most frequently mutated genes in ctDNA were telomerase reverse transcriptase (TERT), tumor protein 53 (TP53), and catenin beta 1 (CTNNB1). A TERT ctDNA mutation and high alpha-fetoprotein (AFP) level were independent predictors of poorer overall survival. cfDNA/ctDNA profiling may be useful for predicting the therapeutic outcome in u-HCC patients treated with Atezo/Bev therapy.

CANCERS (2022)

Add to Collection

Article Oncology

Clinical Usefulness of Monitoring Muscle Volume during Atezolizumab Plus Bevacizumab Therapy in Patients with Unresectable Hepatocellular Carcinoma

Hiroaki Matsumoto et al.

Summary: The decrease of skeletal muscle mass index during atezolizumab plus bevacizumab therapy is significantly associated with poor progression-free survival in patients with unresectable hepatocellular carcinoma, while pretreatment sarcopenia is not a significant factor. Monitoring skeletal muscle volume during immunotherapy may be useful for predicting clinical outcomes.

CANCERS (2022)

Add to Collection

Article Gastroenterology & Hepatology

Comparison of the prognostic effect of sarcopenia on atezolizumab plus bevacizumab and lenvatinib therapy in hepatocellular carcinoma patients

Katsuya Toshida et al.

Summary: The study found that sarcopenia does not affect the prognosis in ATZ/BEV therapy, and therapeutic efficacy can still be expected even in cases of sarcopenia. However, in LEN therapy, patients with sarcopenia have a worse prognosis, with poorer PFS and OS.

JGH OPEN (2022)

Add to Collection

Review Oncology

Comparative assessment of early mortality risk upon immune checkpoint inhibitors alone or in combination with other agents across solid malignancies: a systematic review and meta-analysis

Giuseppe Viscardi et al.

Summary: This study analyzed the incidence of early death (ED) in randomized clinical trials (RCTs) using immune checkpoint inhibitors. The results showed that the risk of ED was higher when immune checkpoint inhibitors were used alone compared to non-immune checkpoint inhibitor therapies, while the risk was lower when they were used in combination with other therapies. Patients with gastric cancer and urothelial carcinoma were at a higher risk of ED. PD-L1 expression and the class of immune checkpoint inhibitor drugs were not associated with ED.

EUROPEAN JOURNAL OF CANCER (2022)

Add to Collection

Article Gastroenterology & Hepatology

Impact of older age in patients receiving atezolizumab and bevacizumab for hepatocellular carcinoma

Mathew Vithayathil et al.

Summary: This study investigated the efficacy and safety of combination therapy with atezolizumab and bevacizumab in older patients with hepatocellular carcinoma. The results showed that there were no significant differences in treatment outcomes and safety between older and younger patients.

LIVER INTERNATIONAL (2022)

Add to Collection

Article Oncology

Virtual clinical trials of anti-PD-1 and anti-CTLA-4 immunotherapy in advanced hepatocellular carcinoma using a quantitative systems pharmacology model

Richard J. Sove et al.

Summary: This study uses quantitative systems pharmacology (QSP) framework to conduct a virtual clinical trial for nivolumab and ipilimumab in HCC patients. The model incorporates detailed biological mechanisms of immune cell-cancer cell interactions and generates virtual patients for the trial. The predictions of the model are consistent with clinically observed outcomes, demonstrating the potential of QSP models in patient selection and trial design.

JOURNAL FOR IMMUNOTHERAPY OF CANCER (2022)

Add to Collection

Article Oncology

Pretreatment Positron Emission Tomography with 18F-Fluorodeoxyglucose May Be a Useful New Predictor of Early Progressive Disease following Atezolizumab plus Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma

Yusuke Kawamura et al.

Summary: The utility of F-18-fluorodeoxyglucose positron emission tomography/computed tomography (F-18-FDG-PET/CT) as a predictor of early progressive disease (e-PD) in hepatocellular carcinoma (HCC) patients treated with atezolizumab plus bevacizumab (Atezo/Bev) was investigated in this study. The results showed that a tumor-to-normal liver ratio (TLR) >= 2, indicating higher oncological aggressiveness, was associated with lower objective response rates, higher e-PD rates, and worse early progression-free survival (e-PFS). Pretreatment F-18-FDG-PET/CT may be a useful new predictor of e-PD and may enable early decision-making based on early treatment changes following Atezo/Bev treatment of HCC.

ONCOLOGY (2022)

Add to Collection

Article Oncology

Pretreatment Modified Albumin-Bilirubin Grade Is an Important Predictive Factor Associated with the Therapeutic Response and the Continuation of Atezolizumab plus Bevacizumab Combination Therapy for Patients with Unresectable Hepatocellular Carcinoma

Takashi Tanaka et al.

Summary: This study aimed to investigate the predictive factors and therapeutic continuation of atezolizumab plus bevacizumab treatment for patients with unresectable hepatocellular carcinoma (u-HCC). The study found that pre-treatment modified albumin-bilirubin grades 1 and 2a were important predictive factors associated with therapeutic response and continuation of treatment.

CURRENT ONCOLOGY (2022)

Add to Collection

Article Oncology

Effect of Atezolizumab plus Bevacizumab in Patients with Hepatocellular Carcinoma Harboring CTNNB1 Mutation in Early Clinical Experience

Keita Ogawa et al.

Summary: The treatment effect of ATZ/BV in patients with HCC with CTNNB1 mutation is comparable to those without CTNNB1 mutation.

JOURNAL OF CANCER (2022)

Add to Collection

Review Biochemistry & Molecular Biology

Emerging new therapeutic antibody derivatives for cancer treatment

Shijie Jin et al.

Summary: This review article introduces the potential of monoclonal antibodies as targeted anticancer agents and their applications in cancer therapy. It also discusses various types of antibodies, clinical study advances, and the rationale and mechanisms of different antibody formats. Well-designed novel antibodies are paving the way for successful treatments of various cancers in the clinic.

SIGNAL TRANSDUCTION AND TARGETED THERAPY (2022)

Add to Collection

Article Gastroenterology & Hepatology

Therapeutic efficacy of ramucirumab after lenvatinib for post-progression treatment of unresectable hepatocellular carcinoma

Atsushi Hiraoka et al.

Summary: In a retrospective study, 28 patients with u-HCC who received lenvatinib were switched to ramucirumab treatment, with therapeutic response obtained in only 26 patients and a low objective response rate observed. Disease progression was the main reason for discontinuation of ramucirumab treatment.

GASTROENTEROLOGY REPORT (2021)

Add to Collection

Article Oncology

Pembrolizumab plus lenvatinib with or without hepatic arterial infusion chemotherapy in selected populations of patients with treatment-naive unresectable hepatocellular carcinoma exhibiting PD-L1 staining: a multicenter retrospective study

Song Chen et al.

Summary: Among treatment-naive patients with unresectable hepatocellular carcinoma exhibiting PD-L1 staining, the PLH regimen may significantly improve survival benefits compared to the PL regimen with a controllable safety profile.

BMC CANCER (2021)

Add to Collection

Article Medicine, General & Internal

Efficacy and Safety of Ramucirumab in Patients with Unresectable Hepatocellular Carcinoma with Progression after Treatment with Lenvatinib

Kayoko Kasuya et al.

Summary: This study assessed the early anti-tumor response to ramucirumab (RAM) as a second-line treatment for advanced unresectable hepatocellular carcinoma (uHCC) after lenvatinib (LEN) treatment. Results suggest that RAM may have the potential to suppress uHCC progression and maintain liver function during treatment, supporting the importance of evaluating alpha-fetoprotein (AFP) trends for predicting RAM effectiveness.

INTERNAL MEDICINE (2021)

Add to Collection

Article Gastroenterology & Hepatology

Atezolizumab and bevacizumab combination compared with sorafenib as the first-line systemic treatment for patients with unresectable hepatocellular carcinoma: A cost-effectiveness analysis in China and the United states

Feng Wen et al.

Summary: This study assessed the cost-effectiveness of atezolizumab and bevacizumab combination therapy as first-line treatment for unresectable HCC patients from the perspectives of Chinese and American payers. The combination therapy was found to be not cost-effective based on the willingness-to-pay threshold in both countries.

LIVER INTERNATIONAL (2021)

Add to Collection

Article Oncology

Is Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma Superior Even to Lenvatinib? A Matching-Adjusted Indirect Comparison

Andrea Casadei-Gardini et al.

Summary: The MAIC analysis demonstrated that the combination of atezolizumab plus bevacizumab is superior to lenvatinib in terms of overall survival. The number needed to treat ranged from seven in the first 12 months to five at the 15th month.

TARGETED ONCOLOGY (2021)

Add to Collection

Article Oncology

First-Line Atezolizumab Plus Bevacizumab versus Sorafenib in Hepatocellular Carcinoma: A Cost-Effectiveness Analysis

Chi-Leung Chiang et al.

Summary: Research shows that atezolizumab-bevacizumab may be cost-effective in treating patients with unresectable hepatocellular carcinoma, depending on factors such as long-term clinical benefits, price reductions, duration of therapy, and dosage optimization. The long-term effectiveness, price reduction, duration of therapy, and dosage optimization are critical determinants of the cost-effectiveness of atezolizumab-bevacizumab in patient treatment.

CANCERS (2021)

Add to Collection

Article Medicine, General & Internal

Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib as First-Line Treatment of Unresectable Hepatocellular Carcinoma

Dan Su et al.

Summary: Cost-effectiveness evaluation of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma from the US payer perspective showed that the treatment is unlikely to be cost-effective compared with sorafenib. Lowering the prices of atezolizumab and bevacizumab may enhance cost-effectiveness, and tailoring treatments based on individual patient factors could also improve economic outcomes.

JAMA NETWORK OPEN (2021)

Add to Collection

Article Oncology

Atezolizumab plus Bevacizumab versus Sorafenib in the Chinese Subpopulation with Unresectable Hepatocellular Carcinoma: Phase 3 Randomized, Open-Label IMbrave150 Study

Shukui Qin et al.

Summary: The study demonstrates that atezolizumab plus bevacizumab significantly improves overall survival and progression-free survival in Chinese patients with unresectable hepatocellular carcinoma compared to sorafenib, with hypertension being the most common grade 3-4 adverse event and other high-grade adverse events being infrequent.

LIVER CANCER (2021)

Add to Collection

Article Medicine, General & Internal

Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma

Xin Zhang et al.

Summary: In this economic evaluation, atezolizumab plus bevacizumab was associated with clinical benefit but was not cost-effective compared with sorafenib for first-line treatment of unresectable or metastatic hepatocellular carcinoma from a US payer perspective. A substantial reduction in price for atezolizumab plus bevacizumab would be needed to achieve favorable cost-effectiveness for this new therapy.

JAMA NETWORK OPEN (2021)

Add to Collection

Review Health Care Sciences & Services

Histone Deacetylase Inhibitors in the Treatment of Hepatocellular Carcinoma: Current Evidence and Future Opportunities

Nikolaos Garmpis et al.

Summary: HCC remains a major health issue globally, with treatment outcomes still suboptimal. In addition to traditional risk factors, epigenetic factors play a role in HCC development. HDACIs, as novel anticancer agents, have shown promising results in targeting HDAC up-regulation in HCC.

JOURNAL OF PERSONALIZED MEDICINE (2021)

Add to Collection

Article Oncology

Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma

Antonio D'Alessio et al.

Summary: The combination of atezolizumab plus bevacizumab has become the current standard of care for first-line treatment of unresectable or metastatic HCC, showing superior efficacy. Further research is needed to assess treatment sequencing and subsequent therapies.

EXPERT REVIEW OF ANTICANCER THERAPY (2021)

Add to Collection

Article Gastroenterology & Hepatology

Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria

Takuya Sho et al.

Summary: This study evaluated the real-world effectiveness of atezolizumab plus bevacizumab in patients with unresectable HCC, especially those who did not meet the eligibility criteria of the IMbrave150 trial. The results showed that the combination therapy had good safety and efficacy at the early treatment phase for most patients.

HEPATOLOGY RESEARCH (2021)

Add to Collection

Article Oncology

Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial

Peter R. Galle et al.

Summary: The study evaluated patient-reported outcomes (PROs) with atezolizumab plus bevacizumab versus sorafenib in patients with advanced hepatocellular carcinoma. Results showed clinically meaningful benefits in terms of patient-reported quality of life, functioning, and disease symptoms with atezolizumab plus bevacizumab compared with sorafenib.

LANCET ONCOLOGY (2021)

Add to Collection

Article Oncology

Characterization of response to atezolizumab plus bevacizumab versus sorafenib for hepatocellular carcinoma: Results from the IMbrave150 trial

Riad Salem et al.

Summary: The IMbrave150 trial demonstrated significant improvement in clinical outcomes with atezolizumab + bevacizumab compared to sorafenib in unresectable hepatocellular carcinoma patients, showing higher objective response rate and deeper response depth.

CANCER MEDICINE (2021)

Add to Collection

Article Oncology

Atezolizumab and Bevacizumab in Patients with Unresectable Hepatocellular Carcinoma: Pharmacokinetic and Safety Assessments Based on Hepatic Impairment Status and Geographic Region

Colby S. Shemesh et al.

Summary: The study evaluated the pharmacokinetics and safety of unresectable hepatocellular carcinoma patients receiving first-line atezolizumab + bevacizumab, showing that varying levels of hepatic impairment and geographic regions influenced drug concentrations. However, the overall results indicated considerable exposure overlap across groups, with treatment being tolerable in all groups.

LIVER CANCER (2021)

Add to Collection

Article Oncology

Early Tumor Response and Safety of Atezolizumab Plus Bevacizumab for Patients with Unresectable Hepatocellular Carcinoma in Real-World Practice

Yuwa Ando et al.

Summary: The study aimed to investigate the early tumor response and safety of atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma patients. The results showed that AFP may be useful in assessing early response, and the treatment was safe, including in patients with prior MTA treatments, although adverse events were more frequent in patients with prior treatment.

CANCERS (2021)

Add to Collection

Article Oncology

Initial Experience of Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma in Real-World Clinical Practice

Hideki Iwamoto et al.

Summary: The study retrospectively evaluated the efficacy and safety of atezolizumab plus bevacizumab for HCC patients, showing that it remains effective and safe in real-world clinical practice.

CANCERS (2021)

Add to Collection

Article Oncology

Pretreatment Neutrophil-to-Lymphocyte Ratio as a Predictive Marker of Response to Atezolizumab Plus Bevacizumab for Hepatocellular Carcinoma

Yuji Eso et al.

Summary: Pretreatment neutrophil-to-lymphocyte ratio (NLR) may serve as a useful predictor of therapeutic response to Atezo/Bev therapy in patients with HCC, as patients who achieved disease control had significantly lower NLR values compared to those with disease progression, and patients with NLR ≤ 3.21 demonstrated significantly better progression-free survival than those with NLR > 3.21.

CURRENT ONCOLOGY (2021)

Add to Collection

Article Oncology

Comparison of the Clinical Outcome of Ramucirumab for Unresectable Hepatocellular Carcinoma with That of Prior Tyrosine Kinase Inhibitor Therapy

Kei Amioka et al.

Summary: The study found that the AFP response to ramucirumab and the treatment response to prior TKI therapy are associated with treatment response to ramucirumab.

ONCOLOGY (2021)

Add to Collection

Review Oncology

Hepatocellular carcinoma, novel therapies on the horizon

Imane El Dika et al.

Summary: Hepatocellular carcinoma (HCC) is a common and deadly form of liver cancer. The discovery of tyrosine kinase inhibitors (TKIs) has led to advancements in treatment options, ushering in a new era for HCC therapy.

CHINESE CLINICAL ONCOLOGY (2021)

Add to Collection

Meeting Abstract Oncology

Pembrolizumab for advanced anal squamous cell carcinoma (ASCC): Results from the multicohort, phase II KEYNOTE-158 study

Aurelien Marabelle et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Gastroenterology & Hepatology

Incidence of microsatellite instability-high hepatocellular carcinoma among Japanese patients and response to pembrolizumab

Tomokazu Kawaoka et al.

HEPATOLOGY RESEARCH (2020)

Add to Collection

Article Oncology

Predictors of Response and Survival in Immune Checkpoint Inhibitor-Treated Unresectable Hepatocellular Carcinoma

Pei-Chang Lee et al.

CANCERS (2020)

Add to Collection

Article Medicine, General & Internal

Atezolizumab plus Bevacizumab in Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

NEW ENGLAND JOURNAL OF MEDICINE (2020)

Add to Collection

Article Oncology

Real-World Outcomes of Nivolumab in Patients With Unresectable Hepatocellular Carcinoma in an Endemic Area of Hepatitis B Virus Infection

Pil Soo Sung et al.

FRONTIERS IN ONCOLOGY (2020)

Add to Collection

Article Oncology

Phase Ib Study of Lenvatinib Plus Pembrolizumab in Patients With Unresectable Hepatocellular Carcinoma

Richard S. Finn et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study

Michael S Lee et al.

LANCET ONCOLOGY (2020)

Add to Collection

Editorial Material Oncology

Child Pugh and ALBI grade: past, present or future?

Margherita Rimini et al.

ANNALS OF TRANSLATIONAL MEDICINE (2020)

Add to Collection

Article Cell Biology

Vascular endothelial growth factor receptor-2 and its association with tumor immune regulatory gene expression in hepatocellular carcinoma

Ze-Long Liu et al.

Aging-US (2020)

Add to Collection

Review Immunology

Monoclonal Antibodies in Cancer Therapy

David Zahavi et al.

ANTIBODIES (2020)

Add to Collection

Article Oncology

Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study

Aurelien Marabelle et al.

JOURNAL OF CLINICAL ONCOLOGY (2020)

Add to Collection

Article Oncology

Phase 2 study of pembrolizumab and circulating biomarkers to predict anticancer response in advanced, unresectable hepatocellular carcinoma

Lynn G. Feun et al.

CANCER (2019)

Add to Collection

Review Biotechnology & Applied Microbiology

Durvalumab in cancer medicine: a comprehensive review

Juliana Alvarez-Argote et al.

EXPERT OPINION ON BIOLOGICAL THERAPY (2019)

Add to Collection

Article Oncology

Ramucirumab after sorafenib in patients with advanced hepatocellular carcinoma and increased α-fetoprotein concentrations (REACH-2): a randomised, double-blind, placebo-controlled, phase 3 trial

Andrew X. Zhu et al.

LANCET ONCOLOGY (2019)

Add to Collection

Article Oncology

Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial

Andrew X. Zhu et al.

LANCET ONCOLOGY (2018)

Add to Collection

Article Oncology

Benefit-Risk Summary of Regorafenib for the Treatment of Patients with Advanced Hepatocellular Carcinoma That Has Progressed on Sorafenib

Lorraine Pelosof et al.

ONCOLOGIST (2018)

Add to Collection

Review Gastroenterology & Hepatology

Ten years of sorafenib in hepatocellular carcinoma: Are there any predictive and/or prognostic markers?

Giorgia Marisi et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2018)

Add to Collection

Review Oncology

Cardiotoxicity with vascular endothelial growth factor inhibitor therapy

Rhian M. Touyz et al.

NPJ PRECISION ONCOLOGY (2018)

Add to Collection

Review Oncology

Non-transplant therapies for patients with hepatocellular carcinoma and Child-Pugh-Turcotte class B cirrhosis

Alessandro Granito et al.

LANCET ONCOLOGY (2017)

Add to Collection

Editorial Material Biotechnology & Applied Microbiology

PharmGKB summary: sorafenib pathways

Li Gong et al.

PHARMACOGENETICS AND GENOMICS (2017)

Add to Collection

Review Gastroenterology & Hepatology

From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world

Dimitrios Dimitroulis et al.

WORLD JOURNAL OF GASTROENTEROLOGY (2017)

Add to Collection

Review Oncology

Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor

Liting Guo et al.

JOURNAL OF CANCER (2017)

Add to Collection

Review Oncology

Immune Checkpoint Inhibitors in Challenging Populations

Douglas B. Johnson et al.

CANCER (2017)

Add to Collection

Review Biotechnology & Applied Microbiology

Pembrolizumab (Keytruda)

Gerry Kwok et al.

HUMAN VACCINES & IMMUNOTHERAPEUTICS (2016)

Add to Collection

Article Pharmacology & Pharmacy

Tremelimumab

Drugs in research & development (2013)

Add to Collection

Review Oncology

Increased Risk of Serious Hemorrhage with Bevacizumab in Cancer Patients: A Meta-Analysis

Sanjaykumar Hapani et al.

ONCOLOGY (2010)

Add to Collection

Article Medicine, General & Internal

Sorafenib in advanced hepatocellular carcinoma

Josep M. Llovet et al.

NEW ENGLAND JOURNAL OF MEDICINE (2008)

Add to Collection

© Peeref 2019-2024. All rights reserved.